Cavelier Marine, Hervouët Charles, Varin Rémi, Gondé Henri
Department of Pharmacy, CHU Rouen, Normandie University, UNIROUEN, EA7510 ESCAPE, F-76000, Rouen, France.
Department of Pharmacy, CHU Rouen, F-76000, Rouen, France.
Eur J Pediatr. 2025 Mar 14;184(4):252. doi: 10.1007/s00431-025-06080-1.
Compounding oral liquids is a common practice in pediatrics given the scarcity of medications suitable for children. However, compounded products are unlicensed. Their safety, effectiveness and quality are not assessed by regulatory agencies. Then, the assessment of critical characteristics of compounded medications relies on compounding pharmacies. Since the osmolality of oral liquids may contribute to gastrointestinal complications, this study aimed to evaluate the osmolality of compounded oral liquid medications. The osmolality of compounded liquid medications listed in the formulary of our institution was measured. The source of the active pharmaceutical ingredient and the vehicle of each compounded medication were collected. Results showed that 61% of the 28 compounded medications exceeded the recommended threshold of 450 mOsm/kg. The primary determinant of osmolality was found to be the vehicle used in compounding, with commercial vehicles being associated with higher osmolality values. The active pharmaceutical ingredient had minimal influence on the osmolality.
These findings underscore the importance of the vehicle in the osmolality of compounded oral liquids. Careful selection of compounding vehicles is required to minimize the risks associated with high-osmolality medications, especially for vulnerable populations such as enterally fed neonates. The systematic assessment of osmolality of compound medication would support the implementation of strategies to mitigate the risks associated with high osmolality and improve the safety of compounded pediatric medications.
• Compounded oral liquid medications are widely used in pediatrics due to the limited availability of commercial pediatric formulations. • High osmolality in liquid oral medications may contribute to adverse effects.
• This study highlighted the significant impact of the compounding vehicle on the osmolality of compounded oral liquid medications. • Careful selection of compounding vehicles is important, especially for vulnerable children.
鉴于适合儿童的药物稀缺,配制口服液在儿科是一种常见做法。然而,配制产品是未经许可的。其安全性、有效性和质量未经监管机构评估。因此,对配制药物关键特性的评估依赖于配制药房。由于口服液的渗透压可能导致胃肠道并发症,本研究旨在评估配制口服液药物的渗透压。测量了本机构配方中列出的配制液体药物的渗透压。收集了每种配制药物的活性药物成分来源和溶媒。结果显示,28种配制药物中有61%超过了推荐的450毫摩尔/千克阈值。发现渗透压的主要决定因素是配制中使用的溶媒,商业溶媒与较高的渗透压值相关。活性药物成分对渗透压的影响最小。
这些发现强调了溶媒在配制口服液渗透压中的重要性。需要谨慎选择配制溶媒,以尽量减少与高渗药物相关的风险,特别是对于肠内喂养的新生儿等弱势群体。对配制药物渗透压的系统评估将支持实施减轻高渗相关风险的策略,并提高配制儿科药物的安全性。
• 由于商业儿科制剂供应有限,配制口服液药物在儿科广泛使用。• 液体口服药物中的高渗透压可能导致不良反应。
• 本研究强调了配制溶媒对配制口服液药物渗透压的重大影响。• 谨慎选择配制溶媒很重要,特别是对于易受影响的儿童。